Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cathepsin C | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium vivax | dipeptidyl aminopeptidase 3, putative | cathepsin C | 141 aa | 152 aa | 22.4 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Encystation-specific protease | 0.0087 | 0.215 | 0.215 |
Schistosoma mansoni | cyclin B3 | 0.0163 | 0.6334 | 0.6334 |
Trypanosoma brucei | mitotic cyclin 6 | 0.0102 | 0.297 | 1 |
Trichomonas vaginalis | cyclin B, putative | 0.0102 | 0.297 | 0.5712 |
Echinococcus granulosus | cyclins | 0.0053 | 0.0258 | 0.0408 |
Echinococcus multilocularis | cyclin b3 | 0.0053 | 0.0258 | 0.0408 |
Echinococcus multilocularis | cyclins | 0.0053 | 0.0258 | 0.0408 |
Trichomonas vaginalis | cyclin D, putative | 0.0053 | 0.0258 | 0.0497 |
Echinococcus granulosus | cyclin B | 0.0102 | 0.297 | 0.4689 |
Entamoeba histolytica | cyclin, putative | 0.0102 | 0.297 | 1 |
Giardia lamblia | Hypothetical protein | 0.0053 | 0.0258 | 0.0258 |
Trichomonas vaginalis | cyclins, putative | 0.0062 | 0.0764 | 0.147 |
Trichomonas vaginalis | cyclin A, putative | 0.0102 | 0.297 | 0.5712 |
Trichomonas vaginalis | cyclin B, putative | 0.0102 | 0.297 | 0.5712 |
Loa Loa (eye worm) | hypothetical protein | 0.0102 | 0.297 | 0.4689 |
Schistosoma mansoni | cyclin B | 0.0102 | 0.297 | 0.297 |
Giardia lamblia | Dipeptidyl-peptidase I precursor | 0.0087 | 0.215 | 0.215 |
Schistosoma mansoni | dipeptidyl-peptidase I (C01 family) | 0.023 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0102 | 0.297 | 0.4689 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0053 | 0.0258 | 0.0497 |
Echinococcus multilocularis | cyclin B | 0.0102 | 0.297 | 0.4689 |
Echinococcus multilocularis | cyclins | 0.0053 | 0.0258 | 0.0408 |
Plasmodium falciparum | cyclin | 0.0053 | 0.0258 | 0.0258 |
Trichomonas vaginalis | cyclins, putative | 0.0053 | 0.0258 | 0.0497 |
Plasmodium falciparum | dipeptidyl aminopeptidase 1 | 0.023 | 1 | 1 |
Echinococcus granulosus | cyclins | 0.0053 | 0.0258 | 0.0408 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.0062 | 0.0099 |
Trypanosoma cruzi | cyclin 6, putative | 0.0102 | 0.297 | 1 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0163 | 0.6334 | 1 |
Loa Loa (eye worm) | cyclin domain-containing protein | 0.0163 | 0.6334 | 1 |
Echinococcus multilocularis | cyclin B3 1 | 0.0053 | 0.0258 | 0.0408 |
Echinococcus multilocularis | cyclins | 0.0053 | 0.0258 | 0.0408 |
Echinococcus multilocularis | cyclins | 0.0053 | 0.0258 | 0.0408 |
Trichomonas vaginalis | cyclins, putative | 0.0102 | 0.297 | 0.5712 |
Toxoplasma gondii | cathepsin CPC1 | 0.023 | 1 | 1 |
Toxoplasma gondii | preprocathepsin c precursor, putative | 0.023 | 1 | 1 |
Echinococcus granulosus | cyclins | 0.0053 | 0.0258 | 0.0408 |
Leishmania major | CYC2-like cyclin, putative,cyclin 6, putative | 0.0102 | 0.297 | 1 |
Schistosoma mansoni | cyclins | 0.0053 | 0.0258 | 0.0258 |
Plasmodium vivax | dipeptidyl aminopeptidase 2, putative | 0.023 | 1 | 1 |
Trichomonas vaginalis | cyclin B3, putative | 0.0053 | 0.0258 | 0.0497 |
Toxoplasma gondii | cathepsin CPC2 | 0.0087 | 0.215 | 0.215 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0102 | 0.297 | 0.4689 |
Trichomonas vaginalis | cyclins, putative | 0.0102 | 0.297 | 0.5712 |
Entamoeba histolytica | cyclin family protein | 0.0053 | 0.0258 | 0.087 |
Trichomonas vaginalis | cyclin B, putative | 0.0102 | 0.297 | 0.5712 |
Giardia lamblia | Dipeptidyl-peptidase I precursor | 0.0087 | 0.215 | 0.215 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0102 | 0.297 | 0.4689 |
Echinococcus multilocularis | cyclins | 0.0053 | 0.0258 | 0.0408 |
Giardia lamblia | Cyclin A | 0.0053 | 0.0258 | 0.0258 |
Giardia lamblia | G2/mitotic-specific cyclin B | 0.0102 | 0.297 | 0.297 |
Echinococcus granulosus | G2:mitotic specific cyclin B3 | 0.0163 | 0.6334 | 1 |
Echinococcus multilocularis | G2:mitotic specific cyclin B3 | 0.0163 | 0.6334 | 1 |
Leishmania major | cyclin | 0.0102 | 0.297 | 1 |
Plasmodium vivax | dipeptidyl aminopeptidase 3, putative | 0.0087 | 0.215 | 0.215 |
Echinococcus multilocularis | cyclins | 0.0053 | 0.0258 | 0.0408 |
Echinococcus granulosus | cyclins | 0.0053 | 0.0258 | 0.0408 |
Entamoeba histolytica | cyclin, putative | 0.0053 | 0.0258 | 0.087 |
Trichomonas vaginalis | cyclin B, putative | 0.0053 | 0.0258 | 0.0497 |
Trichomonas vaginalis | cyclins, putative | 0.0102 | 0.297 | 0.5712 |
Echinococcus granulosus | cyclin b3 | 0.0053 | 0.0258 | 0.0408 |
Plasmodium falciparum | dipeptidyl aminopeptidase 3 | 0.0087 | 0.215 | 0.215 |
Trichomonas vaginalis | cyclin B, putative | 0.0102 | 0.297 | 0.5712 |
Trypanosoma cruzi | cyclin, putative | 0.0102 | 0.297 | 1 |
Trichomonas vaginalis | cyclin D, putative | 0.0053 | 0.0258 | 0.0497 |
Echinococcus multilocularis | cyclins | 0.0053 | 0.0258 | 0.0408 |
Echinococcus granulosus | cyclin B3 1 | 0.0053 | 0.0258 | 0.0408 |
Echinococcus granulosus | cyclins | 0.0053 | 0.0258 | 0.0408 |
Trichomonas vaginalis | Clan CA, family C1, cathepsin B-like cysteine peptidase | 0.0143 | 0.52 | 1 |
Trichomonas vaginalis | cyclins, putative | 0.0102 | 0.297 | 0.5712 |
Entamoeba histolytica | cyclin family protein | 0.0053 | 0.0258 | 0.087 |
Plasmodium vivax | dipeptidyl aminopeptidase 1, putative | 0.023 | 1 | 1 |
Trypanosoma cruzi | cyclin, putative | 0.0102 | 0.297 | 1 |
Trypanosoma cruzi | CYC2-like cyclin, putative | 0.0102 | 0.297 | 1 |
Onchocerca volvulus | 0.0102 | 0.297 | 1 | |
Plasmodium falciparum | dipeptidyl aminopeptidase 2 | 0.023 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.